OTUD7a Accelerates Pathological Cardiac Hypertrophy via TAK1 Activation
Our findings, for the first time, provide evidence supporting OTUD7a as a novel promoter of pathological cardiac hypertrophy and indicate that targeting the OTUD7a-TAK1 axis represents a promising therapeutic strategy for cardiac hypertrophy and related heart failure.
Authors
- Yanna Sun (ORCID: https://orcid.org/0009-0004-9716-733X)
- Qingqing Wu (ORCID: https://orcid.org/0000-0001-8087-2420)
- Zhe Zheng (ORCID: https://orcid.org/0000-0003-0055-2940)
- Xiaofang Wang (ORCID: https://orcid.org/0000-0003-3782-9800)
- Jinhua Cao
- Lu Gao
- Youyou Du (ORCID: https://orcid.org/0000-0002-5694-2844)
- Sen Guo (ORCID: https://orcid.org/0000-0001-5067-4140)
- Xiaoyang Ji (ORCID: https://orcid.org/0009-0009-4666-958X)
- Lili Xiao (ORCID: https://orcid.org/0000-0003-0542-2723)
- Yue Li (ORCID: https://orcid.org/0009-0003-6759-8588)
- X.D. Cai (ORCID: https://orcid.org/0009-0001-6369-2425)
- Ke Li (ORCID: https://orcid.org/0009-0007-3113-4115)
Institutions
- Xuzhou Medical College (CN)
- Wuhan University (CN)
- Zhongnan Hospital of Wuhan University (CN)
- Xuzhou Construction Machinery Group (China) (CN)
- Xuzhou No.1 People's Hospital (CN)
Publication Details
- Journal
- Circulation Research
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1161/circresaha.125.326647
- Citations
- 1
- Primary Topic
- NF-κB Signaling Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.94